These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 34507552)

  • 21. Melanoma Vaccine--AVAX Technologies: DNP-VACC, M-Vax.
    BioDrugs; 2003; 17(1):69-72. PubMed ID: 12534322
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low-dose adjuvant interferon for stage III malignant melanoma.
    Inman JL; Russell GB; Savage P; Levine EA
    Am Surg; 2003 Feb; 69(2):127-30. PubMed ID: 12641352
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A qualitative assessment of psychosocial impact, coping and adjustment in high-risk melanoma patients and caregivers.
    Tan JD; Butow PN; Boyle FM; Saw RP; O'Reilly AJ
    Melanoma Res; 2014 Jun; 24(3):252-60. PubMed ID: 24584097
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The patient experience of patient-centered communication with nurses in the hospital setting: a qualitative systematic review protocol.
    Newell S; Jordan Z
    JBI Database System Rev Implement Rep; 2015 Jan; 13(1):76-87. PubMed ID: 26447009
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF
    Schadendorf D; Hauschild A; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Larkin J; Nyakas M; Dutriaux C; Haydon A; Robert C; Mortier L; Lesimple T; Plummer R; Schachter J; Dasgupta K; Manson S; Koruth R; Mookerjee B; Kefford R; Dummer R; Kirkwood JM; Long GV
    Lancet Oncol; 2019 May; 20(5):701-710. PubMed ID: 30928620
    [TBL] [Abstract][Full Text] [Related]  

  • 26. KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma.
    Luke JJ; Ascierto PA; Carlino MS; Gershenwald JE; Grob JJ; Hauschild A; Kirkwood JM; Long GV; Mohr P; Robert C; Ross M; Scolyer RA; Yoon CH; Poklepovic A; Rutkowski P; Anderson JR; Ahsan S; Ibrahim N; M Eggermont AM
    Future Oncol; 2020 Jan; 16(3):4429-4438. PubMed ID: 31870188
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SEOM clinical guideline for the management of cutaneous melanoma (2020).
    Majem M; Manzano JL; Marquez-Rodas I; Mujika K; Muñoz-Couselo E; Pérez-Ruiz E; de la Cruz-Merino L; Espinosa E; Gonzalez-Cao M; Berrocal A
    Clin Transl Oncol; 2021 May; 23(5):948-960. PubMed ID: 33651321
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adjuvant therapies in the treatment of stage II and III malignant melanoma.
    Kavanagh D; Hill AD; Djikstra B; Kennelly R; McDermott EM; O'Higgins NJ
    Surgeon; 2005 Aug; 3(4):245-56. PubMed ID: 16121769
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Decision-Making and Health-Related Quality of Life in Patients with Melanoma Considering Adjuvant Immunotherapy.
    Atkinson TM; Hay JL; Young Kim S; Schofield E; Postow MA; Momtaz P; Warner AB; Shoushtari AN; Callahan MK; Wolchok JD; Li Y; Chapman PB
    Oncologist; 2023 Apr; 28(4):351-357. PubMed ID: 36745014
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Melanoma: An update on systemic therapies.
    Skudalski L; Waldman R; Kerr PE; Grant-Kels JM
    J Am Acad Dermatol; 2022 Mar; 86(3):515-524. PubMed ID: 34915056
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial.
    Dreno B; Thompson JF; Smithers BM; Santinami M; Jouary T; Gutzmer R; Levchenko E; Rutkowski P; Grob JJ; Korovin S; Drucis K; Grange F; Machet L; Hersey P; Krajsova I; Testori A; Conry R; Guillot B; Kruit WHJ; Demidov L; Thompson JA; Bondarenko I; Jaroszek J; Puig S; Cinat G; Hauschild A; Goeman JJ; van Houwelingen HC; Ulloa-Montoya F; Callegaro A; Dizier B; Spiessens B; Debois M; Brichard VG; Louahed J; Therasse P; Debruyne C; Kirkwood JM
    Lancet Oncol; 2018 Jul; 19(7):916-929. PubMed ID: 29908991
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adjuvant therapy for melanoma.
    Sondak VK; Wolfe JA
    Curr Opin Oncol; 1997 Mar; 9(2):189-204. PubMed ID: 9161800
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial.
    Wallack MK; Sivanandham M; Balch CM; Urist MM; Bland KI; Murray D; Robinson WA; Flaherty L; Richards JM; Bartolucci AA; Rosen L
    J Am Coll Surg; 1998 Jul; 187(1):69-77; discussion 77-9. PubMed ID: 9660028
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adjuvant immunotherapy for melanoma.
    Thomas D; Bello DM
    J Surg Oncol; 2021 Mar; 123(3):789-797. PubMed ID: 33595889
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ASO Author Reflections: Important Factors for Adjuvant Immunotherapy Treatment Decisions for Stage II-IV Melanoma Patients and Their Clinicians.
    Livingstone A; Morton RL
    Ann Surg Oncol; 2020 Feb; 27(2):585-586. PubMed ID: 31673944
    [No Abstract]   [Full Text] [Related]  

  • 36. [Impact of French consensus conference concerning the follow-up of patients surgically treated for stage I melanoma among French dermatologists and oncologists].
    Bafounta ML; Beauchet A; Poisson-Salomon AS; Saiag P
    Ann Dermatol Venereol; 1999 Nov; 126(11):795-800. PubMed ID: 10612855
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunotherapy for Melanoma.
    Albittar AA; Alhalabi O; Glitza Oliva IC
    Adv Exp Med Biol; 2020; 1244():51-68. PubMed ID: 32301010
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk stratification of sentinel node-positive melanoma patients defines surgical management and adjuvant therapy treatment considerations.
    Verver D; van Klaveren D; van Akkooi ACJ; Rutkowski P; Powell BWEM; Robert C; Testori A; van Leeuwen BL; van der Veldt AAM; Keilholz U; Eggermont AMM; Verhoef C; Grünhagen DJ
    Eur J Cancer; 2018 Jun; 96():25-33. PubMed ID: 29660597
    [TBL] [Abstract][Full Text] [Related]  

  • 39. "Often Relatives are the Key […]" -Family Involvement in Treatment Decision Making in Patients with Advanced Cancer Near the End of Life.
    Laryionava K; Hauke D; Heußner P; Hiddemann W; Winkler EC
    Oncologist; 2021 May; 26(5):e831-e837. PubMed ID: 33037846
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of High Risk Resected Melanoma in Australia: Current Landscape and Practises.
    Bhave P; Haydon A
    Australas J Dermatol; 2020 Aug; 61(3):203-209. PubMed ID: 32403192
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.